. Diagnostic value of HMGB-1 and Acetylcholinesterase in Assessing the Prognosis of Patients with Acute Pancreatitis
Diagnostic value of HMGB-1 and Acetylcholinesterase
Abstract
Aim: Acute pancreatitis (AP) is a disorder of tissue digestion caused by abnormal activation of pancreatic enzymes, which may lead to multi-organ failure and ultimately death as the disease progresses. How to quickly and accurately evaluate the progression of AP has always been a hotspot and difficulty in clinical research.
Methods: Sixty-four AP patients admitted to our hospital from August 2022 to June 2023 and 60 concurrent healthy people were selected as the research subjects, with AP patients as the observation group and healthy people as the control group. Using kits from Wuhan Fine Biotechnology Co., Ltd., an enzyme-linked immunosorbent assay (ELISA) was carried out to measure HMGB-1 and AChE levels. In addition, an automatic biochemical analyzer was utilized to quantify the levels of nutritional proteins albumin (ALB), transferrin (TRF), and total protein (TP) in the observation group.
Results: Compared with the control group, the HMGB-1 in the observation group was higher while the AChE was lower (P<0.05). ROC curve analysis showed that when HMGB-1 was less than 7.25 mg/L, the sensitivity and specificity for diagnosing AP were 89.06% and 51.67%, respectively (P<0.05); when AChE was less than 6.18 U/L, the sensitivity for diagnosing AP was 43.75% and the specificity was 90.00% (P<0.05). Using the joint detection Log(P)=-1.736+(0.645×HMGB-1)+(-0.454×AChE), it was found that HMGB-1+AChE had a sensitivity of 48.44% and a specificity of 88.33% for the diagnosis of AP (P<0.05, cut-off>0.639,)
Conclusion: In this study, we found elevated HMGB-1 expression in AP and reduced acetylcholinesterase (AChE), suggesting that both of them may be involved in the occurrence and development of AP. Meanwhile, the two demonstrated excellent diagnostic efficacy in the onset and poor prognosis of AP, and were closely related to AP progression, confirming their potential as new clinical indicators for AP. Due to the self-digestion by pancreatic enzymes, the nutritional metabolism of AP patients is disrupted, so protein loss is also a focus of attention. In this study, we also found a negative correlation of nutritional protein levels with HMGB-1 in AP patients and a positive correlation between them with AChE, further supporting the relationship between the two and AP progression. The findings can lay a reliable foundation for future research on the diagnosis and treatment of AP based on HMGB-1 and AChE.
References
2. Mederos MA, Reber HA, Girgis MD. Acute Pancreatitis: A Review. JAMA. 2021;325(4):382-90.
3. Valverde-Lopez F, Martinez-Cara JG, Redondo-Cerezo E. Acute pancreatitis. Med Clin (Barc). 2022;158(11):556-63.
4. Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20(5):795-800.
5. Casciaro M, Di Salvo E, Gangemi S. HMGB-1 in Psoriasis. Biomolecules. 2021;12(1).
6. Nogueira-Machado JA, de Oliveira Volpe CM. HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(3):201-9.
7. Jo IJ, Bae GS, Park KC, Choi SB, Jung WS, Jung SY, et al. Scolopendra subspinipes mutilans protected the cerulein-induced acute pancreatitis by inhibiting high-mobility group box protein-1. World J Gastroenterol. 2013;19(10):1551-62.
8. Richbart SD, Merritt JC, Nolan NA, Dasgupta P. Acetylcholinesterase and human cancers. Adv Cancer Res. 2021;152:1-66.
9. Rajagopalan V, Venkataraman S, Rajendran DS, Vinoth Kumar V, Kumar VV, Rangasamy G. Acetylcholinesterase biosensors for electrochemical detection of neurotoxic pesticides and acetylcholine neurotransmitter: A literature review. Environ Res. 2023;227:115724.
10. Eckroat TJ, Manross DL, Cowan SC. Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015-Present: Synthesis and Biological Activity. Int J Mol Sci. 2020;21(17).
11. Bestall SM, Hulse RP, Blackley Z, Swift M, Ved N, Paton K, et al. Sensory neuronal sensitisation occurs through HMGB-1-RAGE and TRPV1 in high-glucose conditions. J Cell Sci. 2018;131(14).
12. Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, et al. Acute Pancreatitis: Diagnosis and Treatment. Drugs. 2022;82(12):1251-76.
13. Alberti P, Pando E, Mata R, Vidal L, Roson N, Mast R, et al. Evaluation of the modified computed tomography severity index (MCTSI) and computed tomography severity index (CTSI) in predicting severity and clinical outcomes in acute pancreatitis. J Dig Dis. 2021;22(1):41-8.
14. Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2019;16(8):479-96.
15. Garg R, Rustagi T. Management of Hypertriglyceridemia Induced Acute Pancreatitis. Biomed Res Int. 2018;2018:4721357.
16. Zhang X, Xie H, Liu Z, Zhang J, Deng L, Wu Q, et al. HMGB 1 acetylation mediates trichloroethylene-induced immune kidney injury by facilitating endothelial cell-podocyte communication. Ecotoxicol Environ Saf. 2023;259:115042.
17. Yang J, Tang X, Wu Q, Ren P, Yan Y, Liu W, et al. Heparin Protects Severe Acute Pancreatitis by Inhibiting HMGB-1 Active Secretion from Macrophages. Polymers (Basel). 2022;14(12).
18. Pohanka M. Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase. Curr Med Chem. 2020;27(18):2994-3011.
19. Khuanjing T, Palee S, Chattipakorn SC, Chattipakorn N. The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: From cells to patient reports. Acta Physiol (Oxf). 2020;228(2):e13396.
20. Garg PK, Singh VP. Organ Failure Due to Systemic Injury in Acute Pancreatitis. Gastroenterology. 2019;156(7):2008-23.
21. Gliem N, Ammer-Herrmenau C, Ellenrieder V, Neesse A. Management of Severe Acute Pancreatitis: An Update. Digestion. 2021;102(4):503-7.
22. Zerem E, Kurtcehajic A, Kunosic S, Zerem Malkocevic D, Zerem O. Current trends in acute pancreatitis: Diagnostic and therapeutic challenges. World J Gastroenterol. 2023;29(18):2747-63.
Copyright (c) 2024 yan li
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.